Aging is the result of the accumulation of a wide variety of molecular and cellular damages over time, meaning that “the more damage we accumulate, the higher the possibility to develop age-related diseases”. Therefore, to reduce the incidence of such diseases and improve human health, it becomes important to find ways to combat such damage. In this sense, geroprotectors have been suggested as molecules that could slow down or prevent age-related diseases. On the other hand, nutraceuticals are another set of compounds that align with the need to prevent diseases and promote health since they are biologically active molecules (occurring naturally in food) that, apart from having a nutritional role, have preventive properties, such as antioxidant, anti-inflammatory and antitumoral, just to mention a few. Therefore, in the present review using the specialized databases Scopus and PubMed we collected information from articles published from 2010 to 2023 in order to describe the role of nutraceuticals during the aging process and, given their role in targeting the hallmarks of aging, we suggest that they are potential geroprotectors that could be consumed as part of our regular diet or administered additionally as nutritional supplements.
Background/Objectives: Insomnia has been widely associated with cognitive impairment (CI). However, the relationship between the two entities (insomnia and CI) is poorly understood. In this context, adults with insomnia show metabolic changes, including alterations in the catabolism of branched-chain amino acids, glycerophospholipids, and glutathione and glutamate biosynthesis. Nevertheless, aging itself induces metabolic changes that may be amplified by chronic diseases that compromise the health of the elderly. Therefore, in the present study we aim to characterise metabolomic profiles of insomnia and CI alone in order to address a significant gap in current research regarding the pathways through which insomnia may lead to CI in older persons. Methods: In this study we perform a targeted metabolomics analysis (UPLC-MS) on 80 serum samples from the Cohort of Obesity, Sarcopenia, and Frailty of Older Mexican Adults (COSFOMA); these samples were classified into four groups (control, insomnia, CI, and insomnia + CI). Results: Our results show that insomnia increases the concentration of acylcarnitines (C10, C8, C14, C12:1, C18:1 and C18) as compared to CI group, while older persons with CI show a decrease the concentration of the acylcarnitines C16, C10 and C8. Finally, individuals with both conditions (insomnia + CI) show that only the concentration of the acylcarnitine C16 decreases compared to controls. Conclusions: Taken together, our results shed light on the relevance of insomnia on lipid metabolism in older persons.
Background/Objectives: Sarcopenia significantly increases the risk of hospitalization and mortality in older adults. However, the prevalence by sex varies across populations and according to the criteria used by the European Working Group on Sarcopenia in Older People 2 (EWGSOP2). Hence, in the current study, we aim to characterize the prevalence of sarcopenia by jointly evaluating all three diagnostic domains in a Mexican cohort of older adults subscribed to a health insurance plan. Methods: We performed binomial and multinomial regression models, ordinal logistic regression, and multiple linear regression from the data corresponding to muscle mass (ASMI), muscle strength (handgrip dynamometry), and physical performance (SPPB) from 556 Mexican older adults (62.2% female; 72.27 ± 6.35 y.o.) categorized by sarcopenia severity according to the EWGSOP2. Results: Men exhibited significantly higher absolute muscle mass and strength across all categories (p < 0.001). Additionally, our statistical analyses demonstrate that age, but not sex, is involved in sarcopenia severity in this population. Moreover, when analyzing the disaggregated EWGSOP2 domains, the results demonstrate that sex is significantly associated with muscle mass (ASMI) and muscle strength (Handgrip strength). Conclusions: These results suggest that sex only influences both muscle mass (ASMI) and muscle strength (handgrip strength) while sarcopenia severity only depends on age.